Amgen Company Profile (NASDAQ:AMGN)

Analyst Ratings

Consensus Ratings for Amgen (NASDAQ:AMGN) (?)
Ratings Breakdown: 1 Sell Rating(s), 9 Hold Rating(s), 12 Buy Rating(s)
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $184.75 (7.86% upside)

Analysts' Ratings History for Amgen (NASDAQ:AMGN)
Show:
DateFirmActionRatingPrice TargetActions
7/28/2016Barclays PLCReiterated RatingEqual Weight$185.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/28/2016Piper Jaffray Cos.Reiterated RatingBuy$193.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/28/2016Morgan StanleyBoost Price TargetOverweight$198.00 -> $199.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/28/2016Jefferies GroupBoost Price TargetBuy$187.00 -> $198.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/28/2016Credit Suisse Group AGReiterated RatingBuy$206.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/28/2016Leerink SwannReiterated RatingMarket Perform$186.00 -> $201.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/28/2016BMO Capital MarketsReiterated RatingOutperform$186.00 -> $190.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/28/2016Robert W. BairdReiterated RatingNeutral$157.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/13/2016Bank of America Corp.Reiterated RatingHold$182.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/29/2016Goldman Sachs Group Inc.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/29/2016Sanford C. BernsteinInitiated CoverageMarket Perform$161.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/18/2016Royal Bank Of CanadaReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/17/2016Cowen and CompanyReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/25/2016Citigroup Inc.Initiated CoverageNeutral$165.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/23/2016BTIG ResearchReiterated RatingSell$135.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/22/2016JPMorgan Chase & Co.Reiterated RatingNeutral$165.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/8/2016ArgusLower Price TargetBuy$202.00 -> $185.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/22/2016Wells Fargo & Co.Reiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/18/2015Atlantic SecuritiesInitiated CoverageOverweight$202.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/22/2015NomuraReiterated RatingBuy$190.00 -> $191.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/31/2015Raymond James Financial Inc.Initiated CoverageMarket PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/17/2015Deutsche Bank AGReiterated RatingBuy$195.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/29/2014 forward)

Earnings

Earnings History for Amgen (NASDAQ:AMGN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
7/28/2016        
7/27/2016Q216$2.74$2.84$5.58 billion$5.69 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/28/2016Q116$2.60$2.90$5.32 billion$5.53 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
1/28/2016Q415$2.29$2.61$5.53 billion$5.54 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/28/2015Q315$2.38$2.72$5.32 billion$5.72 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/30/2015Q215$2.43$2.57$5.32 billion$5.37 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/21/2015Q115$2.10$2.48$4.91 billion$5.03 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
1/27/2015Q414$2.05$2.16$5.20 billion$5.33 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/27/2014Q314$2.11$2.30$4.95 billion$5.03 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/29/2014Q214$2.07$2.37$4.90 billion$5.18 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/22/2014Q114$1.94$1.87$4.76 billion$4.52 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
1/28/2014Q413$1.69$1.82$4.81 billion$5.01 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/22/2013Q313$1.78$1.94$4.60 billion$4.75 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/30/2013Q2 2013$1.74$1.89$4.49 billion$4.68 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/23/2013Q1 2013$1.84$1.96$4.37 billion$4.24 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
1/23/2013Q4 2012$1.42$1.40$4.37 billion$4.42 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/23/2012$1.47$1.67ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/26/2012$1.54$1.83ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
1/26/2012$1.22$1.21ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/24/2011$1.29$1.40ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/29/2011$1.29$1.37ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/20/2011$1.29$1.34ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
1/24/2011$1.11$1.17ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Amgen (NASDAQ:AMGN)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20165$2.48$2.84$2.61
Q2 20163$2.66$2.94$2.77
Q3 20163$2.74$3.22$2.91
Q4 20163$2.68$3.17$2.86
Q1 20171$2.82$2.82$2.82
Q2 20171$2.87$2.87$2.87
Q3 20171$2.87$2.87$2.87
Q4 20171$2.91$2.91$2.91
(Data provided by Zacks Investment Research)

Dividends

Current Dividend Information for Amgen (NASDAQ:AMGN)
Annual Dividend:$4.00
Dividend Yield:2.34%
Payout Ratio:40.90% (Based on Trailing 12 Months of Earnings)
35.71% (Based on Current Year Consensus EPS Estimate)
33.20% (Based on Next Year Consensus EPS Estimate)

Dividend History for Amgen (NASDAQ:AMGN)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable DateShare
7/22/2016quarterly$1.002.4%8/15/20168/17/20169/8/2016Tweet This Announcement  Share This Announcement on StockTwits
3/2/2016quarterly$1.002.74%5/13/20165/17/20166/8/2016Tweet This Announcement  Share This Announcement on StockTwits
12/15/2015quarterly$1.002.43%2/11/20162/16/20163/8/2016Tweet This Announcement  Share This Announcement on StockTwits
10/14/2015quarterly$0.792.07%11/12/201511/16/201512/7/2015Tweet This Announcement  Share This Announcement on StockTwits
7/28/2015quarterly$0.791.84%8/13/20158/17/20159/8/2015Tweet This Announcement  Share This Announcement on StockTwits
3/4/2015quarterly$0.791.98%5/12/20155/14/20156/5/2015Tweet This Announcement  Share This Announcement on StockTwits
12/17/2014quarterly$0.791.88%2/10/20152/12/20153/6/2015Tweet This Announcement  Share This Announcement on StockTwits
10/17/2014quarterly$0.611.77%11/10/201411/13/201412/5/2014Tweet This Announcement  Share This Announcement on StockTwits
7/25/2014quarterly$0.611.99%8/12/20148/14/20149/5/2014Tweet This Announcement  Share This Announcement on StockTwits
3/5/2014quarterly$0.611.96%5/13/20145/15/20146/6/2014Tweet This Announcement  Share This Announcement on StockTwits
12/13/2013quarterly$0.612.18%2/11/20142/13/20143/7/2014Tweet This Announcement  Share This Announcement on StockTwits
10/16/2013quarterly$0.471.62%11/12/201311/14/201312/6/2013Tweet This Announcement  Share This Announcement on StockTwits
7/26/2013quarterly$0.471.72%8/14/20138/16/20139/6/2013Tweet This Announcement  Share This Announcement on StockTwits
3/6/2013quarterly$0.472.02%5/14/20135/16/20136/7/2013Tweet This Announcement  Share This Announcement on StockTwits
12/13/2012quarterly$0.472.11%2/11/20132/13/20133/7/2013Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Amgen (NASDAQ:AMGN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
5/4/2016Madhavan BalachandranEVPSell30,000$154.12$4,623,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/29/2016David BaltimoreDirectorSell3,312$157.21$520,679.52View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/29/2016Sean E HarperEVPSell21,875$157.99$3,456,031.25View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/31/2015Carbonnel Francois DeDirectorSell5,000$153.84$769,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/19/2015Fred HassanDirectorBuy3,010$166.63$501,556.30View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/2/2015Cynthia M PattonSVPSell4,530$157.06$711,481.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/23/2015Stuart A TrossSVPSell3,012$169.31$509,961.72View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/22/2015Sean E HarperEVPSell28,000$171.58$4,804,240.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/3/2015Stuart A TrossSVPSell4,415$157.74$696,422.10View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/2/2015David BaltimoreDirectorSell3,647$158.76$578,997.72View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/11/2015Robert A BradwayCEOSell22,000$152.69$3,359,180.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/5/2015Frank C HerringerDirectorBuy3,000$152.29$456,870.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/3/2014Carbonnel Francois DeDirectorSell3,000$168.01$504,030.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/5/2014Cynthia M PattonSVPSell2,644$127.97$338,352.68View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/5/2014Sean E HarperEVPSell14,000$127.29$1,782,060.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/21/2014Thomas J.W. DittrichCAOSell4,130$112.83$465,987.90View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/28/2014A Kelly MichaelCFOSell2,065$110.45$228,079.25View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/6/2014Carbonnel Francois DeDirectorSell1,000$126.69$126,690.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/4/2013Madhavan BalachandranEVPSell18,000$112.76$2,029,680.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/28/2013David BaltimoreDirectorSell4,582$109.66$502,462.12View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/22/2013Thomas J.W. DittrichCAOSell6,130$104.78$642,301.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/21/2013Madhavan BalachandranEVPSell6,000$103.28$619,680.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/17/2013Rebecca M HendersonDirectorSell8,421$105.72$890,268.12View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/16/2013Cynthia M PattonSVPSell3,544$105.01$372,155.44View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/14/2013Judith C PelhamDirectorSell25,000$108.25$2,706,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Amgen (NASDAQ:AMGN)
DateHeadline
07/28/16 03:29 PMMost Recent Analysts Ratings Report: Amgen Inc. (NASDAQ:AMGN) , DaVita healthCare Partners Inc. (NYSE:DVA) - Street Updates
07/28/16 03:29 PMHC Stocks Overview: Shire PLC (ADR) (NASDAQ:SHPG), Amgen, Inc. (NASDAQ:AMGN) - share market updates (press release)
07/28/16 03:29 PMAmgen, Inc. (AMGN) Posts Strong Q2 Results and Gets Price Target Bumped at BMO Capital - TCC
07/28/16 01:51 PMStreet Talk: Amgen, Dunkin & Cray -
07/28/16 01:27 PMAmgen (AMGN) Stock Higher After Q2 Results, Raised Forecast -
07/28/16 11:08 AMAmgen Inc. 2016 Q2 - Results - Earnings Call Slides
07/28/16 11:08 AMAmgen again raises 2016 forecast in display of confidence
07/28/16 11:08 AMAmgen (AMGN) Q2 Earnings Tops Forecasts, Guides Higher for FY2016
07/28/16 11:08 AMAmgen, Inc. (AMGN) Posts Strong Q2 Results and Gets Price Target Bumped at BMO Capital
07/27/16 08:13 PMWhat to Look for in Amgen Earnings - 24/7 Wall St.
07/27/16 08:13 PMWill Amgen, Inc. (NASDAQ:AMGN) Surprise Investors this Quarter? - Bidness ETC
07/27/16 06:19 PMUPDATE 3-Amgen again raises 2016 forecast in display of confidence - July 27 (Reuters) - Amgen Inc on Wednesday posted higher-than-expected second-quarter profit on strong drug sales and again raised its full-year forecast in a clear signal of management confidence in...
07/27/16 05:41 PMAmgen tops Street 2Q forecasts -
07/27/16 03:33 PMBRIEF-Amgen reports second quarter 2016 financial results - * Sees 2016 capital expenditures to be approximately $700 million
07/27/16 03:17 PMAmgen beats by $0.10, beats on revenue -
07/27/16 02:29 PMThis Hot Stock is Trending: Amgen Inc. (NASDAQ:AMGN) - News Oracle
07/27/16 02:29 PMEarnings Whisper: Groupon Inc (GRPN) and Amgen, Inc. (AMGN) - TCC
07/27/16 11:59 AMTop trade for the 2nd half: Amgen -
07/27/16 11:43 AMWhat to Look for in Amgen Earnings -
07/27/16 10:51 AMMedivation: When Earnings are an Afterthought -
07/27/16 10:42 AMAmgen Inc: What to Watch in Q2 Earnings
07/27/16 06:55 AMAmgen Still Has Many Ways to Win -
07/26/16 12:00 PMHC Stocks Growth: Amgen, Inc. (NASDAQ:AMGN), Opko Health Inc. (NASDAQ:OPK) - share market updates (press release)
07/26/16 12:00 PMStocks With Notable Analysts Assessments: Amgen, Inc. (NASDAQ:AMGN), Crown Castle International Corp (NYSE:CCI) - Review Fortune
07/26/16 12:00 PMHave a Glance at Exelixis, Inc. (NASDAQ:EXEL), Amgen, Inc. (NASDAQ:AMGN) - Post Registrar
07/26/16 12:00 PMAmgen, Inc.: AMGN Stock May Be Prepping for a Surge - Investorplace.com
07/25/16 03:00 PMLamond Capital Partners Exits Position in Amgen (AMGN)
07/25/16 09:25 AMAmgen, Inc.: AMGN Stock May Be Prepping for a Surge - InvestorPlaceInvestorPlace - Stock Market News, Stock Advice & Trading Tips A breakout, relative strength and bid options premiums point to a bullish earnings reaction in AMGN this week. The post Amgen, Inc.: AMGN Stock May Be Prepping for a Surge appeared first on InvestorPlace.
07/25/16 07:14 AMCarter Worth And Mike Khouw's Amgen Trade - Benzinga
07/25/16 07:14 AMAnalysts Observing Stocks Update: Medtronic plc (NYSE:MDT) , Amgen Inc. (NASDAQ:AMGN) - Street Updates
07/25/16 06:36 AMAmgen (AMGN) May Beat Q2 Earnings: Will the Stock Gain? -
07/23/16 02:27 PMStock Performance Rundown on Amgen Inc. (NASDAQ:AMGN) - Engelwood Daily
07/23/16 06:31 AMFriday Session Wrap-up for Amgen Inc. (NASDAQ:AMGN) - Engelwood Daily
07/22/16 07:29 PMAmgen Inc (NASDAQ:AMGN) in Good Position - Street Report
07/22/16 05:58 PMFourth Straight Week Of Gains; Buckle Up For Earnings -
07/22/16 05:08 PMAmgen Announces Webcast Of 2016 Second Quarter Financial Results - [at noodls] - THOUSAND OAKS, Calif., July 22, 2016 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its second quarter financial results on Wednesday, July 27, 2016, after the close of the U.S. ...
07/22/16 05:08 PMAmgen Announces 2016 Third Quarter Dividend - [at noodls] - THOUSAND OAKS, Calif., July 22, 2016 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.00 per share dividend for the third quarter of 2016. The dividend will ...
07/22/16 03:12 PMAmgen declares $1.00 dividend -
07/22/16 02:27 PMIntraday Active Biotech Stocks News: Amgen Inc. (NASDAQ:AMGN), Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) - The Voice Registrar
07/22/16 02:27 PMHC Stocks News Ring: Amgen, Inc. (NASDAQ:AMGN), Novo Nordisk A/S (ADR) (NYSE:NVO) - share market updates (press release)
07/22/16 12:51 PMAmgen 2Q Earnings: Here's What To Expect -
07/22/16 10:39 AMBaird Isn't Changing Its Outlook On Amgen - Benzinga
07/22/16 10:39 AMPrice Target Update: Amgen Inc. (NASDAQ:AMGN) - News Oracle
07/22/16 08:30 AM7 Great Stocks With Rising Dividends -
07/22/16 01:30 AM2:30 am Amgen and UCB submit Biologics License Application to the FDA for Romosozumab -
07/22/16 01:07 AMBRIEF-Amgen and UCB submit biologics license application for romosozumab to the FDA - * Amgen and UCB submit biologics license application for romosozumab to the FDA
07/21/16 08:02 PMStock Update: Amgen Inc
07/21/16 02:27 PMStock Catching Eyes of Investors: Amgen Inc. (NASDAQ:AMGN) - TGP
07/21/16 02:27 PMHigh Expectations Remain For Amgen Inc. (NASDAQ:AMGN) - TGP
07/21/16 02:27 PMHot Biotech Stocks Recap: Exelixis, Inc. (NASDAQ:EXEL), Amgen Inc. (NASDAQ:AMGN) - The Voice Registrar

Social

About Amgen

Amgen logoAmgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company's business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine). The Company focuses its research and development on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience. Its products in Phase III programs include Aranesp for Myelodysplastic syndromes; ENBREL for Psoriatic arthritis and Rheumatoid arthritis remission; IMLYGIC for Metastatic melanoma, and Kyprolis for Multiple myeloma.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: AMGN
  • CUSIP: 03116210
Key Metrics:
  • Previous Close: $171.28
  • 50 Day Moving Average: $157.17
  • 200 Day Moving Average: $153.39
  • P/E Ratio: 18.12
  • P/E Growth: 1.80
  • Market Cap: $128.67B
  • Beta: 0.82
  • Current Year EPS Consensus Estimate: $11.2 EPS
  • Next Year EPS Consensus Estimate: $12.05 EPS
Additional Links:
Amgen (NASDAQ:AMGN) Chart for Friday, July, 29, 2016